Overview

Investigation of Optimal Dosing Conditions for a Long Acting GLP-1 Analogue in Healthy Male Subjects

Status:
Completed
Trial end date:
2012-09-08
Target enrollment:
Participant gender:
Summary
This trial is conducted in Europe. The aim of the trial is to evaluate the optimal dosing conditions for semaglutide (a long acting GLP-1 analogue) in healthy male subjects.
Phase:
Phase 1
Details
Lead Sponsor:
Novo Nordisk A/S